Skip to main content

Table 2 Baseline characteristics of study participants. Data include the mean (±SD) or the number of persons (%)

From: Effectiveness and cost-effectiveness of treatment with additional enrollment to a homeopathic integrated care contract in Germany

  HOM group (n = 1543) CON group (n = 981)
Age (years) 43.1 (±13.6) 43.0 (±12.9)
Women 1208 (78.3) 773 (78.8)
Education, A level or similar 965 (62.5) 542 (55.2)
Utilization of complementary medicine 12 months prior to baseline 955 (61.9) 119 (12.1)
Per-protocol initial anamnesis in HOM group 496 (32.1) N/A
State of residence (n (%))
 Abroad 2 (0.1) 0 (0)
 Baden-Wuerttemberg 185 (12) 105 (10.7)
 Bavaria 206 (13.4) 109 (11.1)
 Berlin 188 (12.2) 59 (6.0)
 Brandenburg 40 (2.6) 33 (3.4)
 Bremen 14 (0.9) 10 (1.0)
 Hamburg 103 (6.7) 56 (5.7)
 Hesse 118 (7.6) 106 (10.8)
 Mecklenburg-Western Pomerania 24 (1.6) 14 (1.4)
 Lower Saxony 123 (8.0) 102 (10.4)
 North-Rhine Westphalia 300 (19.4) 224 (22.8)
 Rhineland-Palatinate 87 (5.6) 49 (5.0)
 Saarland 7 (0.5) 7 (0.7)
 Saxony 22 (1.4) 32 (3.3)
 Saxony-Anhalt 18 (1.2) 13 (1.3)
 Schleswig-Holstein 90 (5.8) 49 (5.0)
 Thuringia 16 (1.0) 13 (1.3)
Diagnosis and specific measures
Migraine/headache (G43.9/ R51) 422 (27.3) 266 (27.1)
 Days with headache (last 4 weeks) 7.2 (±6.1) 6.2 (±5.6)
 Utility valuea 0.683 (±0.118) 0.711 (±0.125)
 Total costs previous 12 months in € (insurer perspective) 1080.82 (±1064.27) 1138.07 (±938.70)
 Total costs previous 12 months in € (societal perspective) 4399.99 (±8472.08) 4476.86 (±7713.43)
Allergic rhinitis (J30.1) 317 (20.5) 188 (19.2)
 RQLQ(S) score 2.5 (±1.3) 1.8 (±1.3)
 AdolRQLQ score 2.0 (±1.0) 2.1 (±1.1)
 Utility valuea 0.727 (±0.124) 0.788 (±0.118)
 Total costs previous 12 months in € (insurer perspective) 912.31 (±872.55) 973.18 (±726.53)
 Total costs previous 12 months in € (societal perspective) 2716.87 (±5866.87) 2867.22 (±5675.07)
Asthma (J45.9) 123 (8.0) 81 (8.3)
 AQLQ(S) score 5.1 (±0.9) 5.5 (±1.1)
 PAQLQ score 4.3 (±1.1) 5.8 (±0.8)
 Utility valuea 0.750 (±0.123) 0.788 (±0.126)
 Total costs previous 12 months in € (insurer perspective) 1233.89 (±1226.28) 1182.97 (±1071.87)
 Total costs previous 12 months in € (societal perspective) 3913.54 (±7459.30) 3191.32 (±5544.62)
Atopic dermatitis (L20) 229 (14.8) 105 (10.7)
 DLQI score 8.9 (±6.1) 6.1 (±5.4)
 CDLQI score 6.6 (±4.3) 2.8 (±2.9)
 Utility valuea 0.743 (±0.128) 0.788 (±0.119)
 Total costs previous 12 months in € (insurer perspective) 929.83 (±874.23) 834.08 (±805.37)
 Total costs previous 12 months in € (societal perspective) 3150.44 (±7876.47) 2644.33 (±3251.03)
Depression (F32.9) 452 (29.3) 341 (34.8)
 BDI-II Score 23.3 (±10.0) 20.3 (±11.3)
 Utility valuea 0.621 (±0.103) 0.666 (±0.123)
 Total costs previous 12 months in € (insurer perspective) 1666.76 (±1821.34) 1737.11 (±1091.65)
 Total costs previous 12 months in € (societal perspective) 10,679.85 (±17,270.82) 7634.41 (±11,252.44)
  1. aDerived from the SF-12